Stromal Cell Derived Factor 1 - Pipeline Review, H2 2019
Stromal Cell Derived Factor 1 - Pipeline Review, H2 2019
SUMMARY
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Stromal Cell Derived Factor 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Stromal cell-derived factor 1 (SDF1) or C-X-C motif chemokine 12 (CXCL12) is a chemokine protein encoded by the CXCL12 gene. It activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. It binds to atypical chemokine receptor ACKR3, which activates the beta-arrestin pathway and acts as a scavenger receptor for SDF-1. It acts as a positive regulator of monocyte migration and a negative regulator of monocyte adhesion via the LYN kinase. It stimulates migration of monocytes and T-lymphocytes through its receptors, CXCR4 and ACKR3, and decreases monocyte adherence to surfaces coated with ICAM-1.
The molecules developed by companies in Phase II and Preclinical stages are 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Genetic Disorders and Immunology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Pancreatic Ductal Adenocarcinoma, B-Cell Chronic Lymphocytic Leukemia, Chronic Heart Failure, Critical Limb Ischemia, Fecal Incontinence, Glioblastoma Multiforme (GBM), Lung Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Myelodysplastic Syndrome, Ovarian Cancer, Pancreatic Cancer, Pancreatic Islet Transplant Rejection, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Traumatic Brain Injury, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis).
Furthermore, this report also reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Stromal Cell Derived Factor 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Stromal cell-derived factor 1 (SDF1) or C-X-C motif chemokine 12 (CXCL12) is a chemokine protein encoded by the CXCL12 gene. It activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. It binds to atypical chemokine receptor ACKR3, which activates the beta-arrestin pathway and acts as a scavenger receptor for SDF-1. It acts as a positive regulator of monocyte migration and a negative regulator of monocyte adhesion via the LYN kinase. It stimulates migration of monocytes and T-lymphocytes through its receptors, CXCR4 and ACKR3, and decreases monocyte adherence to surfaces coated with ICAM-1.
The molecules developed by companies in Phase II and Preclinical stages are 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Genetic Disorders and Immunology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Pancreatic Ductal Adenocarcinoma, B-Cell Chronic Lymphocytic Leukemia, Chronic Heart Failure, Critical Limb Ischemia, Fecal Incontinence, Glioblastoma Multiforme (GBM), Lung Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Myelodysplastic Syndrome, Ovarian Cancer, Pancreatic Cancer, Pancreatic Islet Transplant Rejection, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Traumatic Brain Injury, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis).
Furthermore, this report also reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12)
- The report reviews Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics and enlists all their major and minor projects
- The report assesses Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Overview
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Companies Involved in Therapeutics Development
Biokine Therapeutics Ltd
Chimerix Inc
Juventas Therapeutics Inc
Noxxon Pharma AG
OncoTrap Inc
TikoMed AB
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Drug Profiles
BKT-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dociparstat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBsolvMIR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JVS-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olaptesed pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OT-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CXCL12 for WHIM Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CXCL12 for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Dormant Products
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Discontinued Products
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Product Development Milestones
Featured News & Press Releases
Dec 10, 2019: Chimerix presents updated results from phase 2 clinical trial of DSTAT in refractory myelodysplastic syndrome and acute myeloid leukemia at American Society of Hematology Annual Meeting
Oct 17, 2019: Noxxon Pharma studies combination therapy for brain cancer
Sep 29, 2019: NOXXON presents latest clinical data from phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO Congress
Sep 18, 2019: NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the ESMO Congress
Sep 12, 2019: NOXXON initiates patient recruitment for phase 1/2 Clinical Trial combining NOX-A12 & Radiotherapy for the treatment of Brain Cancer Patients
Jun 24, 2019: NOXXON announces leading international pharma to evaluate NOX-A12 in new indication
Apr 01, 2019: Noxxon presents updated results from phase 1/2 NOX-A12 /Keytruda combination trial at AACR 2019
Mar 04, 2019: TFS International appointed CRO representative for TIKOMED’s phase 2 study in clinical islet transplantation
Feb 28, 2019: NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the 2019 AACR Annual Meeting
Feb 27, 2019: Noxxon Files application for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of Brain Cancer Patients
Dec 14, 2018: NOXXON announces key findings that NOX-A12 plus Keytruda induces an immune response and results in clinical benefit for patients
Dec 10, 2018: NOXXON to present latest clinical data from Nox-A12 / Keytruda combination trial at Esmo Immuno-Oncology Congress
Nov 30, 2018: TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency
Nov 21, 2018: NOXXON to launch NOX-A12 with radiotherapy clinical trial in patients with brain cancer
Nov 19, 2018: TIKOMED granted permission for phase 2 clinical trial in islet cell transplantation by the Swedish Medical Product Agency
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Overview
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Companies Involved in Therapeutics Development
Biokine Therapeutics Ltd
Chimerix Inc
Juventas Therapeutics Inc
Noxxon Pharma AG
OncoTrap Inc
TikoMed AB
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Drug Profiles
BKT-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dociparstat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBsolvMIR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JVS-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olaptesed pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OT-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CXCL12 for WHIM Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CXCL12 for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Dormant Products
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Discontinued Products
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Product Development Milestones
Featured News & Press Releases
Dec 10, 2019: Chimerix presents updated results from phase 2 clinical trial of DSTAT in refractory myelodysplastic syndrome and acute myeloid leukemia at American Society of Hematology Annual Meeting
Oct 17, 2019: Noxxon Pharma studies combination therapy for brain cancer
Sep 29, 2019: NOXXON presents latest clinical data from phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO Congress
Sep 18, 2019: NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the ESMO Congress
Sep 12, 2019: NOXXON initiates patient recruitment for phase 1/2 Clinical Trial combining NOX-A12 & Radiotherapy for the treatment of Brain Cancer Patients
Jun 24, 2019: NOXXON announces leading international pharma to evaluate NOX-A12 in new indication
Apr 01, 2019: Noxxon presents updated results from phase 1/2 NOX-A12 /Keytruda combination trial at AACR 2019
Mar 04, 2019: TFS International appointed CRO representative for TIKOMED’s phase 2 study in clinical islet transplantation
Feb 28, 2019: NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the 2019 AACR Annual Meeting
Feb 27, 2019: Noxxon Files application for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of Brain Cancer Patients
Dec 14, 2018: NOXXON announces key findings that NOX-A12 plus Keytruda induces an immune response and results in clinical benefit for patients
Dec 10, 2018: NOXXON to present latest clinical data from Nox-A12 / Keytruda combination trial at Esmo Immuno-Oncology Congress
Nov 30, 2018: TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency
Nov 21, 2018: NOXXON to launch NOX-A12 with radiotherapy clinical trial in patients with brain cancer
Nov 19, 2018: TIKOMED granted permission for phase 2 clinical trial in islet cell transplantation by the Swedish Medical Product Agency
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Biokine Therapeutics Ltd, H2 2019
Pipeline by Chimerix Inc, H2 2019
Pipeline by Juventas Therapeutics Inc, H2 2019
Pipeline by Noxxon Pharma AG, H2 2019
Pipeline by OncoTrap Inc, H2 2019
Pipeline by TikoMed AB, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Biokine Therapeutics Ltd, H2 2019
Pipeline by Chimerix Inc, H2 2019
Pipeline by Juventas Therapeutics Inc, H2 2019
Pipeline by Noxxon Pharma AG, H2 2019
Pipeline by OncoTrap Inc, H2 2019
Pipeline by TikoMed AB, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Biokine Therapeutics Ltd
Chimerix Inc
Juventas Therapeutics Inc
Noxxon Pharma AG
OncoTrap Inc
TikoMed AB
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Biokine Therapeutics Ltd
Chimerix Inc
Juventas Therapeutics Inc
Noxxon Pharma AG
OncoTrap Inc
TikoMed AB
